2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3126

Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus
Abstract Number: 3127

Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Abstract Number: 3128

Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis
Abstract Number: 3129

Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis
Abstract Number: 3130

Epstein-Barr Virus Induces Activation of Infammatory Markers Via the TLR8 Transduction Pathway in Infected Scleroderma Monocytes
Abstract Number: 3131

Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis
Abstract Number: 3132

Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors
Abstract Number: 3133

The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor
Abstract Number: 3134

Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
Abstract Number: 3135

Incidences and Predictors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal Study
Abstract Number: 3136

Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Abstract Number: 3137

Scleroderma Hand Contracture Study
Abstract Number: 3138

Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis
Abstract Number: 3139

Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms
Abstract Number: 3140

A Meta-Immunochip Analysis Suggests IL12B As a Common Susceptibility Factor for Large-Vessel Vasculitides

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].